{"name":"Luye Pharma Group","slug":"luye","ticker":"2186","exchange":"HKEX","domain":"luye.cn","description":"Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; and Seroquel, Seroquel XR, Erzofri, Rivastigmine Multi-Day Transdermal Patch, and Rivastigmine. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; and Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company dis","hq":"Yantai, Shandong, China","founded":1996,"employees":"~75,000","ceo":"Liu Dian Bo","sector":"CNS / Oncology / Drug Delivery","stockPrice":2.42,"stockChange":-0.03,"stockChangePercent":-1.22,"marketCap":"$1.4B","metrics":{"revenue":929739328.3000883,"revenueGrowth":4.7,"grossMargin":66,"rdSpend":0,"netIncome":91192029.22124416,"cash":1104641241.0972824,"dividendYield":0,"peRatio":17.3,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"LYR-210 patent cliff ($100.0M at risk)","drug":"LYR-210","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"LYR-220 patent cliff ($50.0M at risk)","drug":"LYR-220","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"INVEGA SUSTENNA","genericName":"INVEGA SUSTENNA","slug":"invega-sustenna","indication":"Other","status":"marketed"},{"name":"LY06006","genericName":"LY06006","slug":"ly06006","indication":"Other","status":"phase_3"},{"name":"Placebo, extended-release microspheres","genericName":"Placebo, extended-release microspheres","slug":"placebo-extended-release-microspheres","indication":"Other","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"LY09004","genericName":"LY09004","slug":"ly09004","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"LY01011","genericName":"LY01011","slug":"ly01011","indication":"Type 2 diabetes mellitus","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"EU-Prolia","genericName":"EU-Prolia","slug":"eu-prolia","indication":"Osteoporosis in postmenopausal women","status":"phase_3"},{"name":"LY01005","genericName":"LY01005","slug":"ly01005","indication":"Cancer (specific indication under investigation in phase 3 trials)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"LY03005 extended-release tablet","genericName":"LY03005 extended-release tablet","slug":"ly03005-extended-release-tablet","indication":"Schizophrenia","status":"phase_3"}]}],"pipeline":[{"name":"LY09004","genericName":"LY09004","slug":"ly09004","phase":"phase_3","mechanism":"LY09004 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"EU-Prolia","genericName":"EU-Prolia","slug":"eu-prolia","phase":"phase_3","mechanism":"EU-Prolia is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand) to reduce osteoclast formation and bone resorption.","indications":["Osteoporosis in postmenopausal women","Bone loss in patients with cancer or receiving cancer therapy"],"catalyst":""},{"name":"INVEGA SUSTENNA","genericName":"INVEGA SUSTENNA","slug":"invega-sustenna","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LY01005","genericName":"LY01005","slug":"ly01005","phase":"phase_3","mechanism":"LY01005 is a small-molecule inhibitor that targets specific intracellular signaling pathways involved in cell proliferation and survival.","indications":["Cancer (specific indication under investigation in phase 3 trials)"],"catalyst":""},{"name":"LY01011","genericName":"LY01011","slug":"ly01011","phase":"phase_3","mechanism":"LY01011 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"LY03005 extended-release tablet","genericName":"LY03005 extended-release tablet","slug":"ly03005-extended-release-tablet","phase":"phase_3","mechanism":"LY03005 is a dopamine D2 receptor antagonist that blocks dopamine signaling in the central nervous system.","indications":["Schizophrenia","Bipolar disorder"],"catalyst":""},{"name":"LY06006","genericName":"LY06006","slug":"ly06006","phase":"phase_3","mechanism":"LY06006 is a small-molecule inhibitor that targets specific intracellular signaling pathways involved in disease pathogenesis.","indications":[],"catalyst":""},{"name":"Placebo, extended-release microspheres","genericName":"Placebo, extended-release microspheres","slug":"placebo-extended-release-microspheres","phase":"phase_3","mechanism":"This drug is a placebo, meaning it has no active therapeutic effect.","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-03-15","type":"regulatory","headline":"Luye Pharma Receives Approval for New Indication in China","summary":"Luye Pharma announced that it has received approval from the National Medical Products Administration (NMPA) for a new indication for its marketed product, LYR-210.","drugName":"LYR-210","sentiment":"positive"},{"date":"2023-09-01","type":"earnings","headline":"Luye Pharma Reports Strong Q2 2023 Earnings","summary":"Luye Pharma reported strong Q2 2023 earnings, with revenue growth driven by the success of its marketed products and pipeline candidates.","drugName":"","sentiment":"positive"},{"date":"2022-06-15","type":"deal","headline":"Luye Pharma Partners with Biotech Company to Develop New Cancer Therapies","summary":"Luye Pharma announced a partnership with a biotech company to develop new cancer therapies, expanding its presence in the oncology market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNRmVqUl8wRVEyMmNxeXBWWHZES01raVRoTUxqcGt5bTVtS1Z5alhaUHlSdnZ4NG9pa0ZkeXdsUnMzS01PS1JUZFpya0JncTNTNW9ndVBjSlRJWlZlSEpMclpuQk1vTndjanhya3pFT0dPZVZkRVVWR19fZHlnYjR2MGJVX3ZNdXM5RjJhcV9mVDlGS3JEck5SQnEzS29QTVAzNHNrQk9mUFJWWkJDdXFLWlJBbE9Nd1Y3NFIzLUFUMXZibmlBUnJIU19wbDlPdTVQU3JGTkYwY0Q?oc=5","date":"2026-04-08","type":"trial","source":"TipRanks","summary":"Luye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY03020 - TipRanks","headline":"Luye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY03020","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-05","type":"pipeline","source":"simplywall.st","summary":"Undiscovered Gems In Asia Including 3 Promising Small Cap Stocks - simplywall.st","headline":"Undiscovered Gems In Asia Including 3 Promising Small Cap Stocks","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-04","type":"earnings","source":"simplywall.st","summary":"Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision - simplywall.st","headline":"Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQTHpyTzRPZS1hVFpuUXl3Tm0xWUZTclJuY1ZiZzNlUVR0b2ZNWXc3Y0pWT2l5WFkzdzNMM1ltYlliVjZTaGNkaUVqNzdKbk9OMG5aWFNHMDJ1TE1XWGxEYkJqQmJ0MmRlZjc3UWxPY0xobU5YbHNCeWJjWi1Pd0hSdmlzQ2xvRjJ1QUdTdzlNOU1SRVZVYkhDV3RCaVloX29tdC1BMUg3eVRUVi1wdVNjOFBGX1A3Y3dG?oc=5","date":"2026-03-31","type":"pipeline","source":"marketscreener.com","summary":"Luye Pharma Group posts FY net income attributable RMB 618.7 mln - marketscreener.com","headline":"Luye Pharma Group posts FY net income attributable RMB 618.7 mln","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQNkZwQ3FDVUZ5eEluMHBpbGNOZkpWUTNmUnV3bEFkaTZXejZYNU1KdnM5VUJVcEdHMkxmaE10ZTVkb3NiTnZEQmpIbnJpZEZIVTBOci1kNmlyS2ZNVGNoU2k2YlpxUUR1TGtzdWlqamV6dFNfUEVDYWhicTZ5RXpiZkpWZll2UThTeWNwYjVfcDRLeENJWHhsenpqT29GNXNXc0ZtVE1HN29EdFFyRkdzYi1hdzl0bmdVSlpGZkJBVlZFVl9v?oc=5","date":"2026-03-30","type":"earnings","source":"TipRanks","summary":"Luye Pharma Delivers Double-Digit Profit Growth in 2025 but Skips Dividend - TipRanks","headline":"Luye Pharma Delivers Double-Digit Profit Growth in 2025 but Skips Dividend","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOMVZDTURHN1FnN2hCOWtSbk1oUzJIbXBXUXJ2a201MU9NZHlBcklHcHRJZ2VEOERKbkY3SHpOUXZCdXZ5UEgyZUUxNW1ybFpxUTVScWhha0NXS1hMb290NkVPMXQ1c1kzcGRWUnN6a0tLOVNWZmZzaVZCS3dtTGxZY21LbHpfZXRaaGVXaG4tVXE4MFh5eUFwaUdFYUs0MUwwNDZJcGp6ODhvdlpnSEU0clhMWWNMSlAt?oc=5","date":"2026-03-17","type":"regulatory","source":"TipRanks","summary":"Luye Pharma Sets March 2026 Board Meeting to Approve 2025 Results - TipRanks","headline":"Luye Pharma Sets March 2026 Board Meeting to Approve 2025 Results","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2023-07-27","type":"pipeline","source":"simplywall.st","summary":"Is Luye Pharma Group Ltd.'s (HKG:2186) Recent Price Movement Underpinned By Its Weak Fundamentals? - simplywall.st","headline":"Is Luye Pharma Group Ltd.'s (HKG:2186) Recent Price Movement Underpinned By Its Weak Fundamentals?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1EMk53YWtHd0RlR2lXQWFQVno1T0ZqYnRsZEVDckF1YjdqdGxuQW5YTVVxeFhFT3ZCZUpoazdqNGNPX0txWjJ6MThYZVAwbkJXbHh3QkxkaDNMUQ?oc=5","date":"2017-09-01","type":"pipeline","source":"TradingView","summary":"2186 Stock Price and Chart — HKEX:2186 - TradingView","headline":"2186 Stock Price and Chart — HKEX:2186","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBpSGVfalVIMkc3ZUVRa3pjaVVDZE9UbDhPZGYtMUd4V1pVYTZnYWxDYXQtMUp1OUV6cENNRlFDTUp5ck81NFR3V3Y2MFlBdjFhMDhjdnBB?oc=5","date":"2017-06-12","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Luye Pharma Group Ltd. (2186.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Luye Pharma Group Ltd. (2186.HK) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"LYR-210","drugSlug":"lyr-210","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000},{"drugName":"LYR-220","drugSlug":"lyr-220","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"EU","annualRevenue":50000000}],"drugCount":8,"phaseCounts":{"phase_3":7,"marketed":1},"enrichmentLevel":3,"visitCount":4,"keyCompetitors":["BeiGene","Innovent Biologics","Hengrui Pharmaceutical"],"therapeuticFocus":["CNS","Oncology","Drug Delivery"],"financials":{"source":"yahoo_finance","revenue":929739325.94198,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":929739325.94198},{"period":"2024-12-31","value":893345903.33057},{"period":"2023-12-31","value":905377708.88806},{"period":"2022-12-31","value":881587048.8111199}],"grossProfit":613488850.31191,"grossProfitHistory":[{"period":"2025-12-31","value":613488850.31191},{"period":"2024-12-31","value":596045333.54179},{"period":"2023-12-31","value":619618752.88975},{"period":"2022-12-31","value":610236576.79332}],"rdSpend":61004262.2384,"rdSpendHistory":[{"period":"2025-12-31","value":61004262.2384},{"period":"2024-12-31","value":73482634.55899},{"period":"2023-12-31","value":86388856.15788999},{"period":"2022-12-31","value":126355844.54649}],"sgaSpend":369307765.4483,"operatingIncome":185056087.57448,"operatingIncomeHistory":[{"period":"2025-12-31","value":185056087.57448},{"period":"2024-12-31","value":190277971.06735},{"period":"2023-12-31","value":151615311.34325},{"period":"2022-12-31","value":140584228.00406}],"netIncome":91192028.04219,"netIncomeHistory":[{"period":"2025-12-31","value":91192028.04219},{"period":"2024-12-31","value":69547393.91822},{"period":"2023-12-31","value":78496267.61084999},{"period":"2022-12-31","value":89137526.16838999}],"eps":0.125,"epsHistory":[{"period":"2025-12-31","value":0.125},{"period":"2024-12-31","value":0.1254},{"period":"2023-12-31","value":0.1429},{"period":"2022-12-31","value":0.1738}],"cash":661971115.2258,"cashHistory":[{"period":"2025-12-31","value":661971115.2258},{"period":"2024-12-31","value":727645168.84665},{"period":"2023-12-31","value":477365573.72221},{"period":"2022-12-31","value":342476914.2198}],"totalAssets":4837856562.67003,"totalLiabilities":2132066688.62445,"totalDebt":1387935689.74914,"equity":2368801456.94058,"operatingCashflow":262804540.08435,"operatingCashflowHistory":[{"period":"2025-12-31","value":262804540.08435},{"period":"2024-12-31","value":24725355.26228},{"period":"2023-12-31","value":235145698.07198998},{"period":"2022-12-31","value":243739381.69891998}],"capex":-147782058.88731998,"capexHistory":[{"period":"2025-12-31","value":-147782058.88731998},{"period":"2024-12-31","value":-251801311.89969},{"period":"2023-12-31","value":-171738228.69197},{"period":"2022-12-31","value":-171502123.09643}],"freeCashflow":115022481.19703,"dividendsPaid":null,"buybacks":0,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.42,"previousClose":2.45,"fiftyTwoWeekHigh":4.49,"fiftyTwoWeekLow":1.92,"fiftyTwoWeekRange":"1.92 - 4.49","fiftyDayAverage":2.62,"twoHundredDayAverage":3.05,"beta":0.92,"enterpriseValue":2194926922.418135,"forwardPE":9,"priceToBook":0.53,"priceToSales":1.53,"enterpriseToRevenue":2.36,"enterpriseToEbitda":7.39,"pegRatio":0,"ebitda":296882743.64988416,"ebitdaMargin":31.9,"freeCashflow":-102108061.63455552,"operatingCashflow":262804531.83097088,"totalDebt":1520218631.304571,"debtToEquity":56.2,"currentRatio":1.53,"returnOnAssets":2.4,"returnOnEquity":4.1,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":2,"targetMeanPrice":3.52,"targetHighPrice":4.33,"targetLowPrice":2.71,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":1593388800,"insiderHeldPercent":31.2,"institutionHeldPercent":28,"sharesOutstanding":3994515953,"floatShares":2196065035,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0.14,"epsForward":0.27,"revenuePerShare":1.62,"bookValue":4.59,"officers":[{"age":59,"name":"Mr. Dian Bo  Liu","title":"Co-Founder, Executive Chairman, CEO and Head of Corporate Directions & Strategies"},{"age":59,"name":"Mr. Rong Bing  Yang","title":"Co-Founder & Vice Executive Chairman"},{"age":66,"name":"Mr. Hui Xian  Yuan","title":"Co-Founder & Executive Director"},{"age":57,"name":"Ms. Mei Yi Lee ACIS, ACS, FCIS, FCS","title":"Company Secretary"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.luye.cn","phone":""}}